omniture
深圳微芯生物科技股份有限公司 Shenzhen Chipscreen Biosciences Co. Ltd.

Latest News

Positive results from Phase II clinical trial (CGZ203 study) of Chiglitazar monotherapy for non-alcoholic steatohepatitis

SHENZHEN, China, March 18, 2024 /PRNewswire/ -- On March 18 2024, Shenzhen chipscreen biosciences C...

2024-03-18 19:25 1088

Chipscreen NewWay: First Patient Dosed in Phase 1 Trial of the Bispecific Antibody NWY001, a Next-generation Tumor Immunotherapy in Patients with Advanced Solid Tumors

CHENGDU, China, Jan. 16, 2024 /PRNewswire/ -- Chengdu Chipscreen NewWay Biosciences Co., Ltd. (NewW...

2024-01-16 17:00 1641

Chipscreen's New Drug Candidate CS32582 Capsules Approved for Clinical Treatment of Psoriasis

SHENZHEN, China, Nov. 2, 2023 /PRNewswire/ -- On Oct. 31, 2023, Shenzhen Chipscreen Biosciences Co....

2023-11-02 15:58 1037

Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Peripheral T-Cell Lymphoma(PTCL) in Japan

SHENZHEN, China, Dec. 1, 2021 /PRNewswire/ -- Shenzhen Chipscreen Biosciences' licensing partner, H...

2021-12-01 21:54 1609

Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Adult T-cell Leukemia/lymphoma in Japan

SHENZHEN, China, June 24, 2021 /PRNewswire/ -- Shenzhen Chipscreen Biosciences' licensing partner, ...

2021-06-24 19:00 1999

Chipscreen received a Phase 1b/2 clinical trial of Chiauranib/CS2164 IND clearance from the US Food and Drug Administration (FDA)

SHENZHEN, China, April 16, 2021 /PRNewswire/ -- Shenzhen Chipscreen Biosciences , aChina headquarter...

2021-04-16 18:24 1887

Chiauranib, an Anti-tumor Drug Developed by Chipscreen, is Given CDE "Breakthrough Therapy Designation"

SHENZHEN, China, Jan. 5, 2021 /RPNewswire/ -- Last December 25, the anti-tumor drug candidate Chiau...

2021-01-05 17:49 2001

Chipscreen and HISUN reach a strategic cooperation

SHENZHEN, China, Dec. 16, 2020 /PRNewswire/ -- On December 16, 2020, SHENZHEN CHIPSCREEN BIOSCIENC...

2020-12-16 17:59 2193

Chipscreen Biosciences's Original New Drug CS12192: Investigational New Drug (IND) Application Accepted

SHENZHEN, China, March 24, 2020 /PRNewswire/ -- On March 23th, 2020, Shenzhen Chipscreen Bioscience...

2020-03-24 19:25 1465

National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) for Breast Cancer Indication

SHENZHEN, China, Nov. 29, 2019 /PRNewswire/ -- On November 29, 2019, Shenzhen Chipscreen Bioscienc...

2019-11-29 20:22 3637

Chipscreen and Novogene enter a strategic partnership for companion diagnostics development

SHENZHEN, China, Oct. 8, 2019 /PRNewswire/ -- Chipscreen Biosciences Co., Ltd. (Chipscreen, Stock S...

2019-10-08 20:46 3329

Chipscreen Biosciences's Oringinal New Drug Bilessglu® (for Type 2 Diabetes): Commercialization Application Accepted

SHENZHEN, China, Sept. 19, 2019 /PRNewswire/ -- The new drug application (NDA) of Chiglitazar (Bile...

2019-09-19 23:02 2160